A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Linde Partners with 3D Medlab in Pioneering Research to Optimize 3D Printing of Complex Structures for Medical Devices

Today Linde announced it has started pioneering research into how atmospheric conditions in the additive manufacturing process can be optimized to produce complex latticed structures for medical devices. In collaboration with 3D Medlab, a leader in additive manufacturing for the medical sector, the joint project is the first of its kind and represents a milestone in the field of orthopedic device development.

Multifaceted, latticed components aim to mimic human body parts and can better assimilate into the patient’s own bone and tissue structure, leading to fewer rejections and quicker healing times. Additive manufacturing can optimize the production of such components ensuring high-quality repeatability of the process and requiring less post-print finishing. However, the atmosphere in the printing chamber needs to be optimal and reproducible.

Atmospheric gases play a fundamental role in the printing process and any impurities that remain in the chamber, even once purged, can have a detrimental effect on the part being manufactured. Additionally, fumes created during the production process can remain on the part, requiring post-production cleaning.

Even extremely small variations in oxygen content can impair the mechanical or chemical properties of metals sensitive to oxygen – such as titanium and aluminum alloys – and can affect the composition of the end product. For the Linde/3D Medlab research trials, the titanium alloy in question is Ti-6AI-4V.

“We are proud to be collaborating with 3D Medlab on this important and forward-looking project,” said Pierre Forêt, Senior Expert Manufacturing, Linde. “As a customer at the forefront of medical device manufacturing, anything less than optimal product outcomes is critically important to avoid, so it is testament to our gases expertise and know-how that we have been selected to partner in this endeavor.”

The atmospheric trials involve a new helium/argon gas mixture created especially by Linde for the project to make the process smoother and cleaner, along with use of Linde’s ADDvance O2 precision, a first-of-a-kind oxygen measuring and analysis technology to ensure the optimal mix of gases within the print chamber. Along with the new gas mixture, ADDvance O2 precision will give 3D Medlab precise, granular control over the oxygen concentration and humidity levels in the print chamber.

“Our experience with Linde shows that they are as committed to the same high standards of precision and excellence in additive manufacturing that we are,” said Gaël Volpi, CEO, 3D Medlab. “Full regulatory compliance is a fundamental cornerstone in our engineering and design process and our customers trust us to ensure all proper measures and controls are in place.”

Linde began its association with 3D Medlab originally through the supply of its ADDvance powder cabinet, designed to retain the quality of valuable, sensitive metal powders used in the additive manufacturing process by protecting them from exposure to ambient air and humidity. While the current collaboration between Linde and 3D Medlab is focused on Ti-6AI-4V lattice structures, future efforts will include the potential of nickel titanium (also known as nitinol) in view of its excellent shape memory and super elasticity, making it an ideal candidate for next generation stents.

SourceLinde
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy